$6.04
0.58% today
Nasdaq, Apr 02, 09:47 pm CET
ISIN
US6700021040
Symbol
NVAX
Sector
Industry

Novavax, Inc. Stock price

$6.00
-1.87 23.76% 1M
-6.32 51.30% 6M
-2.04 25.37% YTD
+1.35 29.03% 1Y
-68.32 91.93% 3Y
-8.03 57.23% 5Y
-160.00 96.39% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
-0.41 6.40%
ISIN
US6700021040
Symbol
NVAX
Sector
Industry

Key metrics

Market capitalization $965.06m
Enterprise Value $294.79m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.43
P/S ratio (TTM) P/S ratio 1.41
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -30.65%
Revenue (TTM) Revenue $682.16m
EBIT (operating result TTM) EBIT $-231.94m
Free Cash Flow (TTM) Free Cash Flow $-100.32m
Cash position $933.74m
EPS (TTM) EPS $-1.32
P/E forward negative
P/S forward 1.91
EV/Sales forward 0.58
Short interest 29.09%
Show more

Is Novavax, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Novavax, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Novavax, Inc. forecast:

4x Buy
57%
2x Hold
29%
1x Sell
14%

Analyst Opinions

7 Analysts have issued a Novavax, Inc. forecast:

Buy
57%
Hold
29%
Sell
14%

Financial data from Novavax, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
682 682
31% 31%
100%
- Direct Costs 196 196
40% 40%
29%
486 486
26% 26%
71%
- Selling and Administrative Expenses 283 283
35% 35%
41%
- Research and Development Expense 387 387
47% 47%
57%
-183 -183
64% 64%
-27%
- Depreciation and Amortization 49 49
18% 18%
7%
EBIT (Operating Income) EBIT -232 -232
58% 58%
-34%
Net Profit -188 -188
66% 66%
-27%

In millions USD.

Don't miss a Thing! We will send you all news about Novavax, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novavax, Inc. Stock News

Negative
Reuters
about 4 hours ago
The U.S. Food and Drug Administration have missed the deadline for making a key decision on Novavax's COVID-19 vaccine, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
Negative
Fast Company
2 days ago
Stocks of major vaccine makers dropped on Monday after the Food and Drug Administration's (FDA) top vaccine official Dr. Peter Marks resigned, citing conflicts with Health and Human Services (HHS) Secretary Robert F. Kennedy (RFK) Jr. over his views on immunization.
Negative
New York Post
2 days ago
Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump administration undertakes an overhaul of federal health agencies.
More Novavax, Inc. News

Company Profile

Novavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Head office United States
CEO John Jacobs
Employees 952
Founded 1987
Website www.novavax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today